TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01117584

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ipragliflozin
Description: oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ipragliflozin
Description: oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ipragliflozin
Description: oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ipragliflozin
Description: oral tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: oral tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metformin
Description: oral tablet
Study: NCT03356444

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone Acetate
Description: Abiraterone Acetate: orally, 1000mg, qd, plus with prednisone orally, 5mg, bid. Course of treatment: Stop the treatment until biochemical, clinical or radiographic progression occurs.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Docetaxel: intravenously, 75 mg/m\^2, over 1 h every 3 weeks, plus with prednisone, orally, 10 mg, qd.~Course of treatment: Stop the treatment until biochemical, clinical or radiographic progression occurs. If no progression, stop until 10 cycles of traetment
Study: NCT02576340

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: otilonium bromide
Description: otilonium bromide was administered before the procedure
Study: NCT03870191

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Injection of either twin block or trigger point injection.
Description: Study participants will be randomized into either group and will receive the intervention.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Injection of either twin block or trigger point injection.
Description: Study participants will be randomized into either group and will receive the intervention.
Study: NCT01927952

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Kirschner wire
Description: Surgical fixation utiliziing Kirschner wire

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Integra IPP-On PIP Fusion System
Description: surgical fixation utilizing the Integra IPP-On PIP Fusion System

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Stryker Smart-Toe Implant
Description: surgical fixation utilizing the Stryker Smart-Toe Implant
Study: NCT04333329

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NEUROLITH
Description: transcranial pulse stimulation (TPS)
Study: NCT02837497

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ICU-RESUS CPR Improvement Bundle
Description: 1. Point-of-care CPR training~2. Post-cardiac arrest educational debriefings
Study: NCT00562679

Intervention type: OTHER
Intervention: There is no intervention
Study: NCT03001154

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-administered Virtual Reality Exposure Therapy
Description: Therapist-guided, Internet-administered Virtual Reality Exposure Therapy self-help program

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Waiting-list
Description: Weekly assessments of public speaking
Study: NCT05798689

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Probiotic administration and gluten
Description: Probiotic preparation including multi-species strains of Lactobacillus and Bacillus. The probiotic was administered at baseline and interrupted after 32 days. At the same time the other arm received placebo. Gluten was provided after 10 days of gluten free diet in increasing amounts
Study: NCT02707913

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BF-Amlodipine Tablet 10mg
Description: BF-Amlodipine Tablet 10mg is a generic product manufactured by Bright Future Pharmaceuticals Factory O/B Bright Future Pharmaceutical Laboratories Limited

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Norvasc Tablet 10mg
Description: Norvasc Tablet 10mg will be used as a comparator drug for the BE study
Study: NCT02214693

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DA-1229

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DA-1229

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DA-1229

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DA-1229
Study: NCT02095899

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Rufinamide
Description: 2x200mg up to max 2x800mg a day Titration over 20days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rufinamide
Description: 2x200mg up to max 2x800mg a day Titration over 20days
Study: NCT01818401

Intervention type: DEVICE
Group type: OTHER
Intervention: the prosthesis GMK ® without the ancillary MyKnee ® LBS

Intervention type: DEVICE
Group type: OTHER
Intervention: Matched patient cutting blocks MyKnee ® LBS
Study: NCT02163954

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ticagrelor
Description: After randomization, an initial loading dose of ticagrelor (180 mg) was given and maintenance doses (ticagrelor 90 mg twice daily) was treated for 14 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Description: After randomization, an initial loading dose of ticagrelor (180 mg) was given and maintenance doses (ticagrelor 90 mg twice daily) was treated for 14 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: After randomization, an initial loading dose of clopidogrel (300 mg) was given and maintenance doses (clopidogrel 75 mg once daily) was treated for 14 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Description: After randomization, an initial loading dose of clopidogrel (300 mg) was given and maintenance doses (clopidogrel 75 mg once daily) was treated for 14 days.
Study: NCT01685606

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cellular immunotherapy
Description: A minimum of 1x108 CD3+ cells and maximum of 2x108 CD3+ cells/kg from a haploidentical donor irrespective of the number of CD34+ cells will be infused.
Study: NCT04141943

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual reality
Description: The patients who are allocated to the VR arm will receive information about radiotherapy via virtual reality.
Study: NCT04645394

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Aronia melanocarpa
Description: Administered once (acute study)

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Aronia melanocarpa
Description: Administered once (acute study)

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Aronia melanocarpa
Description: Administered once (acute study)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Aronia melanocarpa
Description: Administered once (acute study)

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Fermented Aronia Melanocarpa high dose
Description: Administered once (acute study)

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Fermented Aronia Melanocarpa high dose
Description: Administered once (acute study)

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Fermented Aronia Melanocarpa high dose
Description: Administered once (acute study)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Fermented Aronia Melanocarpa high dose
Description: Administered once (acute study)

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Fermented Aronia Melanocarpa low dose
Description: Administered once (acute study)

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Fermented Aronia Melanocarpa low dose
Description: Administered once (acute study)

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Fermented Aronia Melanocarpa low dose
Description: Administered once (acute study)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Fermented Aronia Melanocarpa low dose
Description: Administered once (acute study)

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Administered once (acute study)

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Administered once (acute study)

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Administered once (acute study)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered once (acute study)
Study: NCT02845050

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinflunine
Description: One cycle is defined as a period of 3 weeks of treatment:~Vinflunine (280 mg/m²) on Day 1, every 21 days as a 20 minute IV infusion~Cisplatin (70 mg/m²) on Day 2, every 21 days~4 cycles of neo-adjuvant chemotherapy prior to radical cystectomy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: One cycle is defined as a period of 3 weeks of treatment:~Vinflunine (280 mg/m²) on Day 1, every 21 days as a 20 minute IV infusion~Cisplatin (70 mg/m²) on Day 2, every 21 days~4 cycles of neo-adjuvant chemotherapy prior to radical cystectomy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radical cystectomy
Description: max. 4 weeks after 4 cycles of neo-adjuvant treatment radical cystectomy will be performed
Study: NCT02563613

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Exercise (PE)
Description: Core session: 2 hours, Booster session: 1 hour

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthy Diet (HD)
Description: Core session: 2 hours, Booster session: 1 hour

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Wait-list Control (C)
Description: The wait-list control group will receive the intervention at 3 months.
Study: NCT03419325

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: CYP2C19 test
Description: Patients will be categorized into 4 groups based on the results of their genetic test for CYP2C19 as well as the residual platelet reactivity test (P2RY12 assay=PRU units) and DAPT treatments options will be recommended accordingly (i.e., through a Clinical Decision Support (CDS) tool that is based on a pharmacogenetic-driven algorithm and the PRU result).
Study: NCT05798689

Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo administration and gluten
Description: The placebo was administered at baseline and interrupted after 32 days. At the same time the other arm received probiotic. Gluten was provided after 10 days of gluten free diet in increasing amounts
Study: NCT02562248

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Automated screening for pediatric anxiety
Description: families receiving care at the intervention clinics with concern for disruptive behaviors will be administered the SCARED tool for anxiety in addition to the Vanderbilt tool for ADHD

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: families receiving care at the control clinics with concern for disruptive behaviors will be administered the Vanderbilt tool for ADHD only
Study: NCT06484439

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketorolac
Description: 10 mg PO q 6h scheduled

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone
Description: 5 mg PO PRN

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen
Description: 650 mg q 6h scheduled

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: 650 mg q 6h scheduled

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen
Description: 600 mg PO scheduled q6h

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrocodone
Description: 5 mg hydrocodone PO PRN q6h
Study: NCT00750555

Intervention type: DRUG
Group type: OTHER
Intervention: Erlotinib
Description: 150 mg per day orally until disease progression occurs, up to a maximum of 12 months
Study: NCT02231450

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lu AE58054 encapsulated film-coated tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lu AE58054 encapsulated film-coated tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lu AE58054 encapsulated film-coated tablets
Study: NCT05078099

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CureSight
Description: Binocular eye-tracking-based passive home treatment system delivering personalized amblyopia therapy
Study: NCT01260935

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic Hill Repair
Description: With the Hill repair, stitches are placed right where the esophagus and stomach meet and attached to muscle tissue that is fixed to the spine.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic Nissen Repair
Description: With the Nissen repair, the upper part of the stomach is wrapped around the esophagus, with some anchoring of the wrap at several locations.
Study: NCT04177641

Intervention type: DIAGNOSTIC_TEST
Intervention: Total Oxidant Capacity(μmolH2O2Equiv/L)
Description: Aforementioned oxidative stress markers will be measured via Cobas c501(Roche Diagnostics, Indianapolis, IN, USA) used with sphectrophotometry

Intervention type: DIAGNOSTIC_TEST
Intervention: Total Oxidant Capacity(μmolH2O2Equiv/L)
Description: Aforementioned oxidative stress markers will be measured via Cobas c501(Roche Diagnostics, Indianapolis, IN, USA) used with sphectrophotometry
Study: NCT00730327

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Behavioral modification
Description: Low-calorie diet, food/exercise diary, eating plan, emphasis on exercise
Study: NCT01768819

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Activity
Description: The intervention consisted of elderly-specific physical activity program for one year. During this period a total of 123 physical activity sessions were carried out. Each session lasted 50 minutes and included stretching, aerobic endurance exercises, resistance exercises, activities involving coordination, agility and flexibility, respiratory exercises and relaxation exercises. The sessions took place three times a week, according to American College of Sports Medicine (ACSM) recommendations. Workloads were adjusted for each subject bimonthly according to their capacity. The sessions were standardized and carried out by previously trained physical educators.
Study: NCT00987831

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group B SLE one blood donation
Description: Blood drawing, history, physical examination,medical record review, questionnaires, completion of disease activity measures including SLEDAI,BILAG, CLASI,PGA,PROs,LFA investigational systems, BICLA, SRI
Study: NCT02807519

Intervention type: GENETIC
Intervention: collection of salivary cytokines
Description: Collection of the saliva will be done following this procedure: The collection will be done prior to any other dental manipulation. The test person is sitting with its head tilted slightly forward. Initially, any saliva present in the mouth must be swallowed or spit out completely. Then, a paraffin gum is given to the test person. This paraffin gum must be chewed for minimally 2 and maximally up to 5 minutes. During the time period that the test person is chewing the paraffin gum, the saliva must be spitted into a cup repeatedly, or the saliva can also be let run passively into the cup. The amount of saliva is then weighted (1g equivalent to 1 ml) and a saliva flow rate (ml/min) is calculated and noted.

Intervention type: GENETIC
Intervention: collection of salivary cytokines
Description: Collection of the saliva will be done following this procedure: The collection will be done prior to any other dental manipulation. The test person is sitting with its head tilted slightly forward. Initially, any saliva present in the mouth must be swallowed or spit out completely. Then, a paraffin gum is given to the test person. This paraffin gum must be chewed for minimally 2 and maximally up to 5 minutes. During the time period that the test person is chewing the paraffin gum, the saliva must be spitted into a cup repeatedly, or the saliva can also be let run passively into the cup. The amount of saliva is then weighted (1g equivalent to 1 ml) and a saliva flow rate (ml/min) is calculated and noted.
Study: NCT00987831

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood drawing only Group C
Description: Blood drawing and Brief medical history to ensure status of healthy control

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Group A SLE prospective study
Description: Patients have history and physical exmamination at each visit. Blood is drawn at each visit. At baseline, any background immune suppressant is stopped and patients given depomedrol up to 160 mg IM which can be repeated up to four times in the first two weeks. Patients are seen again at week 2, 4 and monthly until the final flare visit at which time they donate blood, receive appropriate treatments and exit study. Patients may elect to continue in study for up to one year. The following disease activity measures are included: SLEDAI, BILAG, CLASI, PGA, PROs (including lupus PRO and SF-36 ant ptGA), joint counts, exploratory outcome measures,BICLA,SRI
Study: NCT00539708

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Non-invasive ventilation
Description: Non-invasive ventilation after extubation for 24 hours

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Non-invasive ventilation
Description: Non-invasive ventilation after extubation for 24 hours
Study: NCT02286973

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic Acid

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic Acid

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic Acid

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic Acid
Study: NCT00284804

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MDX-060
Description: anti-CD30 monoclonal antibody, i.v. weekly x 3 10 mg/kg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MDX-060
Description: anti-CD30 monoclonal antibody, i.v. weekly x 3 10 mg/kg
Study: NCT04571892

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Super circulating tumor infiltrating lymphocytes(ScTIL)
Description: Peripheral blood mononuclear cells (PBMCs) are used for cell preparation. PD-1(programmed death 1) positive T cells are isolated from peripheral blood by blood cell apheresis method and transduced with lentivirus loaded with enhanced receptor and superamplification factor. The obtained ScTIL is used for one-time intravenous infusion.
Study: NCT03589131

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Total Operative time
Description: Investigators compare the preparation time of the procedure in the operating room and the actual operative time

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Total Operative time
Description: Investigators compare the preparation time of the procedure in the operating room and the actual operative time

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Margin assessment
Description: In this intervention investigators measure the proximal, distal and the important circumferential radial margin away from the tumor to determine if this arm is oncologically safe or not.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Margin assessment
Description: In this intervention investigators measure the proximal, distal and the important circumferential radial margin away from the tumor to determine if this arm is oncologically safe or not.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conversion rate to open surgery
Description: In this interversion investigators try to measure how much is this arm feasible to completely perform the procedure whether robotically or laparoscopically without conversion to open surgery
Study: NCT00730327

Intervention type: OTHER
Group type: OTHER
Intervention: Behavioral modification
Description: Low-calorie diet, food/exercise diary, eating plan, emphasis on exercise
Study: NCT04448951

Intervention type: OTHER
Intervention: transcriptomics
Description: transcriptomics

Intervention type: OTHER
Intervention: transcriptomics
Description: transcriptomics

Intervention type: OTHER
Intervention: transcriptomics
Description: transcriptomics

Intervention type: OTHER
Intervention: flow-cytometry
Description: peripheral blood myeloid cells and lymphocytes flow-cytometry

Intervention type: OTHER
Intervention: flow-cytometry
Description: peripheral blood myeloid cells and lymphocytes flow-cytometry

Intervention type: OTHER
Intervention: flow-cytometry
Description: peripheral blood myeloid cells and lymphocytes flow-cytometry
Study: NCT02856035

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neural feedback plus FES and motor training
Description: We are not testing the feasibility of the imaging methods; that has been well established and is used clinically. We are testing the feasibility of using neural feedback clinical imaging methods in a neural feedback paradigm which involves sequential rtfMRI (phase I) and rtfNIRS (phase II) training; Neurally-triggered, peripherally-directed FES-assist practice of wrist and finger extension will be combined with rtfNIRS training in Phase II; up to 60 total sessions, including additional motor learning sessions without brain neural feedback will be provided in Phase III.
Study: NCT04448951

Intervention type: OTHER
Intervention: cytokines
Description: peripheral blood cytokine analysis

Intervention type: OTHER
Intervention: cytokines
Description: peripheral blood cytokine analysis

Intervention type: OTHER
Intervention: cytokines
Description: peripheral blood cytokine analysis
Study: NCT02866747

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Hypofractionated stereotactic radiation therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofractionated stereotactic radiation therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Study: NCT02014987

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Training programmes
Description: Runners with a high body mass index follow two types of training programmes:~1. a running programme of 3 kilometres per week~2. a running programme 6 kilometres per week~The amount of running will be increased with 10 % per week.